Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label tisotumab vedotin study in advanced solid tumors
2023-503812-34-00Phase 2Authorised
- Sponsor
- Seagen Inc.
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of tisotumab vedotin in Nonhematologic neoplasms, colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 2 more (7 arms), sponsored by Seagen Inc. Primary endpoint: Confirmed objective response rate. Planned start Feb 2024; status: authorised.
02
Drugs
tisotumab vedotin
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-503812-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503812-34-00.